연구동향 분석

WhitenoneCoat Hypertension: the Neglected Subgroup in Hypertension

Cesare Cuspidi Marijana Tadic Giuseppe Mancia Guido Grassi 2018년

논문상세정보
인용/피인용

' WhitenoneCoat Hypertension: the Neglected Subgroup in Hypertension' 의 참고문헌

  • White-coat isolated systolic hypertension is a risk factor for carotid atherosclerosis
    Manios E [2016]
  • White-coat hypertension: a selection bias? Harvest Study Investigators. Hypertension and Ambulatory Recording Venetia Study
    Palatini P [1998]
  • White-coat hypertension, as defined by ambulatory blood pressure monitoring, and subclinical cardiac organ damage: a meta-analysis
    Cuspidi C [2015]
  • White-coat hypertension and cardiovascular events: a meta-analysis
  • White-coat and masked hypertension as risk factors for progression to sustained hypertension: the Finn-Home study
    Siven SS [2016]
  • The sympathetic nervous system alterations in human hypertension
    Grassi G [2015]
  • The heterogeneous nature of white-coat hypertension
    Mancia G [2016]
  • The effect of antihypertensive treatment with dihydropyridine calcium antagonists on white-coat hypertension
    Hoegholm A [1996]
  • Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study
    Tientcheu D [2015]
  • Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population
    Franklin SS [2012]
  • Risk of new onset metabolic syndrome associated with white coat and masked hypertension: data from a general population
    Cuspidi C [2018]
  • Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension
    Fagard RH [2000]
  • Relationship between clinic and ambulatory blood-pressure measurements and mortality
    Banegas JR [2018]
  • Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis
  • Prevalence and clinical outcomes of white-coat and masked hypertension: analysis of a large ambulatory blood pressure database
    Tocci G [2018]
  • Prevalence and clinical characteristics of white-coat hypertension based on different definition criteria in untreated and treated patients
  • Nocturnal blood pressure fall and metabolic syndrome score in patients with white coat hypertension
    Vyssoulis G [2008]
  • Neurogenic abnormalities in masked hypertension
    Grassi G [2007]
  • Metabolic syndrome in subjects with white-coat hypertension: impact on left ventricular structure and function
    Mule G [2007]
  • Long-term risk of sustained hypertension in white-coat or masked hypertension
    Mancia G [2009]
  • Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure
    Mancia G [2006]
  • Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements
    Mancia G [2013]
  • Left ventricular mass and geometry in patients with established hypertension and white coat hypertension
    Hoegholm A [1993]
  • Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values
    Bombelli M [2009]
  • Is white-coat hypertension a risk factor for carotid atherosclerosis? A review and meta-analysis
    Cuspidi C [2015]
  • Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension
    Mancia G [2009]
  • Hypertension in adults: diagnosis and management. Clinical guideline [Internet]
  • Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults
    Leung AA [2017]
  • How reliable is isolated clinical hypertension defined by a single 24-h ambulatory blood pressure monitoring?
    Cuspidi C [2007]
  • How common is white coat hypertension?
  • European Society of Hypertension position paper on ambulatory blood pressure monitoring
  • Effect of long-term antihypertensive treatment on white-coat hypertension
    Mancia G [2014]
  • Does white coat hypertension require treatment over age 80?: Results of the hypertension in the very elderly trial ambulatory blood pressure side project
    Bulpitt CJ [2013]
  • Differential effect of obesity on prevalence of cardiac and carotid target organ damage in hypertension (the Campania Salute Network)
    Mancusi C [2017]
  • Comparison of demographic, clinical, and laboratory parameters between patients with sustained normotension, white coat hypertension, masked hypertension, and sustained hypertension
    Afsar B [2013]
  • Clinical value of ambulatory blood pressure: evidence and limits
    Mancia G [2015]
  • Ambulatory blood pressure normality: results from the PAMELA study
    Mancia G [1995]
  • Ambulatory Blood Pressure Monitoring (ABPM) as the reference standard for diagnosis of hypertension and assessment of vascular risk in adults
    Hermida RC [2015]
  • Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] study)
    Sega R [2001]
  • Adverse prognostic value of persistent office blood pressure elevation in white coat hypertension
    Mancia G [2015]
  • 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines
    Whelton PK [2018]
  • 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
    Mancia G [2013]